ARS Pharmaceuticals, Inc. (SPRY) company profile
Close on Nov 13, 2026Market cap $386.85MP/E –Yield –
About ARS Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the commercialization and development of emergency treatments for severe Type I allergic reactions, including anaphylaxis. The company's principal product is neffy (marketed as EURneffy in the European Union and the United Kingdom), a needle-free intranasal epinephrine spray. Formulated with an absorption enhancer to deliver low-dose epinephrine safely without injections, neffy is offered in 2 mg and 1 mg doses. ARS Pharmaceuticals serves adult and pediatric allergy patients, partnering with and marketing to allergists, pediatricians, primary care doctors, and school health programs.
The company distributes its treatments in the United States and works with collaboration partners to expand commercialization across global markets. Its product has received marketing approvals in the United States, the European Union, the United Kingdom, Japan, Australia, and China, and is under regulatory evaluation in Canada. The provided text does not state the city or location of the company's headquarters.
Summary of the business section of ARS Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ARS Pharmaceuticals, Inc.
- Founded
- 2016
- Headquarters
- San Diego, CA
- Address
- 11682 El Camino Real, Suite 300 92130
- Phone
- (858) 771-9307
- Website
- getneffy.com
- Employees
- 158, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Diego, California
Stock & identifiers
- Ticker
- SPRY
- Former tickers
- SBTX until Nov 8, 2022
- Exchange
- Nasdaq
- IPO date
- Dec 4, 2020
- Shares outstanding
- 99M, Aug 11, 2026
- Public float
- $1.09B, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1671858
- CUSIP
- 82835W108
- ISIN
- US82835W1080
- FIGI
- BBG00FZQGXG3
- Share class FIGI
- BBG00FZQGXH2
- EIN
- 81-1489190
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Donn Casale | President and CEO, Director | – |
| Richard E. Lowenthal | PRESIDENT AND CEO, Director | 15,630,330 |
| John L. Slebir | Chief Legal Officer | – |
| Margaret Ekins Smith | Chief Commercial Officer | – |
| Eric Karas | Chief Commercial Officer | 12,176 |
| Alexander A. Fitzpatrick | Chief Legal Officer | 90,910 |
| Kathleen D. Scott | Chief Financial Officer | 18,292 |
| Sarina Tanimoto | CHIEF MEDICAL OFFICER | 14,786,653 |
| Justin Chakma | Chief Business Officer | 166,380 |
| Brian Dorsey | Chief Operating Officer | 10,789 |
| Capital Healthcare Fund LP RA | Director | 8,365,465 |
| Rajeev M. Shah | Director | 902,904 |
| Peter Kolchinsky | Director | – |
| Ra Capital Management, L.P. | Director | 9,958,073 |
| RA Capital Nexus Fund II, L.P. | Director | – |
| Peter A. Thompson | Director | 0 |
| Brent L. Saunders | Director | 0 |
| Saqib Islam | Director | 15,239 |
| Laura Shawver | Director | 210,346 |
| Pratik Shah | Director | 4,574,554 |
| Rajeev Dadoo | Director | 3,009,677 |
| Michael Kelly | Director | 83,225 |
| Phillip M. Schneider | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $9.66M | $10.25M | $4.09M | $213 | – |
| FY2024 | $7.17M | $14.59M | $3.24M | $193 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Richard Lowenthal President and Chief Executive Officer | $700.00K | $6.18M | $315.00K | $2.47M | $9.66M | +35% |
| Sarina Tanimoto Chief Medical Officer | $540.00K | $2.11M | $178.20K | $2.47M | $5.29M | +25% |
| Justin Chakma Chief Business Officer | $497.00K | $2.21M | $164.00K | $21.70K | $2.89M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Dec 4, 2020
- Offer price
- $21.00
- Securities offered
- 11,500,000
- Gross proceeds
- $241.50M
- Exchange
- Nasdaq
- First trading day
- Dec 4, 2020
- First-day close
- $25.00+19.0%
- Lock-up ends (est.)
- Jun 2, 2021
“The initial public offering price is $21.00 per share of our common stock.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 158 full-time employees and 5 part-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 8, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 8, 2022 | Name change | Name changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc. |
| Oct 6, 2022 | Merger vote | Definitive merger proxy statement |
| Dec 4, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 1, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?